Costimulation Blockade in Vascularized Composite Allotransplantation

13Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Vascular composite allotransplantation (VCA) is a field under research and has emerged as an alternative option for the repair of severe disfiguring defects that result from infections or traumatic amputation in a selected group of patients. VCA is performed in centers with appropriate expertise, experience and adequate resources to effectively manage the complexity and complications of this treatment. Lifelong immunosuppressive therapy, immunosuppression associated complications, and the effects of the host immune response in the graft are major concerns in VCA. VCA is considered a quality of life transplant and the risk-benefit ratio is dissimilar to life saving transplants. Belatacept seems a promising drug that prolongs patient and graft survival in kidney transplantation and it could also be an alternative approach to VCA immunosuppression. In this review, we are summarizing current literature about the role of costimulation blockade, with a focus on belatacept in VCA.

Cite

CITATION STYLE

APA

Giannis, D., Moris, D., & Cendales, L. C. (2020, September 17). Costimulation Blockade in Vascularized Composite Allotransplantation. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2020.544186

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free